Peter Dreger
Overview
Explore the profile of Peter Dreger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
318
Citations
4969
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kramer I, Konig L, Luft T, Hegenbart U, Schonland S, Eichkorn T, et al.
Bone Marrow Transplant
. 2025 Feb;
PMID: 39948382
Allogeneic hematopoietic cell transplantation (alloHCT) is an effective treatment for patients with relapsed/refractory peripheral T-cell lymphoma (PTCL), but the contribution of the conditioning regimen is still unclear. Here we present...
2.
Liebers N, Boumendil A, Finel H, Edelmann D, Kobbe G, Baermann B, et al.
Blood Cancer Discov
. 2025 Feb;
PMID: 39913291
Brexucabtagene autoleucel (brexu-cel) and allogeneic hematopoietic cell transplantation (alloHCT) are effective treatments for relapsed or refractory mantle cell lymphoma (r/r MCL), but the optimal choice remains unclear. We conducted an...
3.
Kolbe C, Kauer J, Brinkmann B, Dreger P, Huber W, Muller-Tidow C, et al.
J Immunother Cancer
. 2025 Jan;
13(1).
PMID: 39884778
Bispecific antibodies (BsAb) have emerged as a leading treatment modality in patients suffering from B-cell non-Hodgkin's lymphoma (B-NHL). However, treatment failure is common and may potentially be attributed to pre-existing...
4.
Limbach M, Kuehl R, Koeppel M, Dreger P, Luft T, Bohus M, et al.
Support Care Cancer
. 2025 Jan;
33(2):89.
PMID: 39794666
Purpose: Physical performance is crucial for prognosis after allogeneic hematopoietic stem cell transplantation (allo-HCT). Cardiorespiratory fitness has already been shown to have prognostic value, and there is increasing evidence that...
5.
Shumilov E, Wurm-Kuczera R, Kerkhoff A, Wang M, Melchardt T, Holtick U, et al.
Blood Adv
. 2024 Dec;
PMID: 39661985
Glofitamab, a bispecific antibody targeting CD20 and CD3, is approved for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) after at least two prior treatment lines, but real-world data is scarce....
6.
Dreger P, Schmitz N
Hematology Am Soc Hematol Educ Program
. 2024 Dec;
2024(1):69-77.
PMID: 39644016
In contrast to B-cell lymphoma, the advent of modern targeting drugs and immunotherapeutics has not led to major breakthroughs in the treatment of peripheral T-cell lymphoma (PTCL) to date. Therefore,...
7.
Bethge W, Flossdorf S, Hanke F, Schmid C, Ringhoffer M, Klein S, et al.
Haematologica
. 2024 Dec;
PMID: 39633549
We investigated the effect of center-specific variables on overall survival (OS) after allogeneic hematopoietic cell transplantation (alloHCT) in acute myeloid leukemia (AML). Eligible were adult patients reported to DRST registry...
8.
Farid K, Bug G, Schmitt A, Lang F, Schubert M, Haberkorn U, et al.
Front Immunol
. 2024 Dec;
15:1500177.
PMID: 39624098
Introduction: CAR T-cell therapy is highly effective, but also associated with unique toxicities. Because of the origin of T cells in patients who previously underwent allogeneic hematopoietic cell transplantation (alloHCT),...
9.
Luft T, Gras L, Koster L, Kroger N, Schroder T, Platzbecker U, et al.
Am J Hematol
. 2024 Nov;
100(1):38-51.
PMID: 39605194
Prophylaxis strategies for Graft versus host disease (GVHD) in allogeneic hematopoietic cell transplantation (allo-HCT) frequently encompass a combination of a calcineurin inhibitor (CNI) with either methotrexate (MTX) or mycophenolate mofetil...
10.
Prasad R, Rehman A, Rehman L, Darbaniyan F, Blumenberg V, Schubert M, et al.
Blood
. 2024 Oct;
145(8):823-839.
PMID: 39441941
Antibiotic (ABX)-induced microbiome dysbiosis is widespread in oncology, adversely affecting outcomes and side effects of various cancer treatments, including immune checkpoint inhibitors and chimeric antigen receptor T-cell (CAR-T) therapies. In...